Coxevac Umoja wa Ulaya - Kislovenia - EMA (European Medicines Agency)

coxevac

ceva santé animale - inaktivirana cepiva coxiella burnetii, sev devet milj - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

Startvac Umoja wa Ulaya - Kislovenia - EMA (European Medicines Agency)

startvac

laboratorios hipra s.a. - escherichia coli j5 inactivated, staphylococcus aureus (cp8) strain sp 140 inactivated, expressing slime-associated antigenic complex - imunologija za bovidae - govedo (krave in telice) - za črede imunizacijo zdravih krav in telic, v mlekarice čred z ponavljajoče se vnetje vimena težav, da se zmanjša pojavnost sub-klinično vnetje vimena in pogostnost in resnost kliničnih znakov klinični vnetje vimena, ki jih povzročajo bakterije staphylococcus aureus, coliforms in coagulase-negativni stafilokoki. celotna imunizacijska shema povzroči imuniteto od približno 13 dni po prvi injekciji do približno 78 dni po tretji injekciji (kar ustreza 130 dni po porodu).

Ubac Umoja wa Ulaya - Kislovenia - EMA (European Medicines Agency)

ubac

laboratorios hipra, s.a. - lipoteichoic kisline iz biofilma oprijem del streptococcus uberis, sev 5616 - imunologija za bovidae - govedo - za aktivno imunizacijo zdravih krav in telic, da zmanjša pojavnost kliničnih intramammary okužb, ki jih povzroča streptococcus uberis, da se zmanjša telesni število celic v streptococcus uberis pozitivno četrtletju vzorcev mleka in zmanjšanje proizvodnje mleka izgube, ki jih povzroča streptococcus uberis intramammary okužb.